Spinal cord injury (SCI) is an incurable condition, in which a cascade of cellular and molecular events triggered by inflammation and excitotoxicity impairs endogenous regeneration, namely remyelination and axonal outgrowth. We designed a treatment solution based on an implantable biomaterial (electrospun poly (l-lactic acid) [PLLA]) loaded with ibuprofen and triiodothyronine (T3) to counteract inflammation, thus improving endogenous regeneration. In vivo efficacy was tested by implanting the drug-loaded PLLA in the rat model of T8 contusion SCI. We observed the expected recovery of locomotion beginning on day 7. In PLLA-implanted rats (i.e., controls), the recovery stabilized at 21 days post-lesion (DPL), after which no further improvement was observed. On the contrary, in PLLA + ibuprofen (Ibu) + T3 (PLLA-Ibu-T3) rats a further recovery and a significant treatment effect were observed, also confirmed by the gait analysis on 49 DPL. Glutamate release at 24 h and 8 DPL was reduced in PLLA-Ibu-T3– compared to PLLA-implanted rats, such as the estimated lesion volume at 60 DPL. The myelin- and 200-neurofilament–positive area fraction was higher in PLLA-Ibu-T3–implanted rats, where the percentage of astrocytes was significantly reduced. The implant of a PLLA electrospun scaffold loaded with Ibu and T3 significantly improves the endogenous regeneration, leading to an improvement of functional locomotion outcome in the SCI.
Get full access to this article
View all access options for this article.
References
1.
van den BergM.E., CastelloteJ.M., Mahillo-FernandezI., and de Pedro-CuestaJ. (2010). Incidence of spinal cord injury worldwide: a systematic review. Neuroepidemiology, 34, 184–192.
2.
SaghazadehA., and RezaeiN, (2017). The role of timing in the treatment of spinal cord injury. Biomed. Pharmacother. 92, 128–139.
3.
RossignolS., SchwabM., SchwartzM., and FehlingsM.G. (2007). Spinal cord injury: time to move?. J. Neurosci. 27, 11782–11792.
4.
HaytaE., EldenH. (2018). Acute spinal cord injury: a review of pathophysiology and potential of non-steroidal anti-inflammatory drugs for pharmacological intervention. J. Chem. Neuroanat. 87, 25–31.
5.
ScholtesF., AdriaensensP., StormeL., BussA., KakulasA.B., GelanJ., BeulsE., SchoenenJ., BrookG.A., and MartinD. (2006). Correlation of postmortem 9.4 tesla magnetic resonance imaging and immunohistopathology of the human thoracic spinal cord 7 months after traumatic cervical spine injury. Neurosurgery, 59, 671–678.
6.
AarabiB., SimardJ.M., KuferaJ.A., AlexanderM., ZacherlK.M., MirvisS.E., ShanmuganathanK., SchwartzbauerG., MaulucciC.M., SlavinJ., AliK., MassettiJ., and EisenbergH.M. (2012). Intramedullary lesion expansion on magnetic resonance imaging in patients with motor complete cervical spinal cord injury. J. Neurosurg. Spine, 17, 243–250.
7.
EvaniewN., Belley-CôtéE.P., FallahN., NoonanV.K., RiversC.S., and DvorakM.F. (2016). Methylprednisolone for the treatment of patients with acute spinal cord injuries: a systematic review and meta-analysis. J. Neurotrauma, 33, 468–481.
8.
StahelP.F., VanderHeidenT., and FinnM.A. (2012). Management strategies for acute spinal cord injury: current options and future perspectives. Curr. Opin. Crit. Care, 18, 651–660.
9.
ShankC.D., WaltersB.C., and HadleyM.N., (2017). Management of acute traumatic spinal cord injuries. Handb. Clin. Neurol. 140, 275–298.
10.
WangX., BudelS., BaughmanK., GouldG., SongK.H., and StrittmatterS.M. (2009). Ibuprofen enhances recovery from spinal cord injury by limiting tissue loss and stimulating axonal growth. J. Neurotrauma, 26, 81–95.
11.
KoppM.A., LiebscherT., WatzlawickR., MartusP., LauferS., BlexC., SchindlerR., JungehulsingG.J., KnüppelS., KreutzträgerM., EkkernkampA., DirnaglU., StrittmatterS.M., NiedeggenA., and SchwabJ.M. (2016). SCISSOR-Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol. BMJ Open, 6, e010651.
12.
BillonN., JolicoeurC., TokumotoY., VennströmB, and RaffM. (2002). Normal timing of oligodendrocyte development depends on thyroid hormone receptor alpha 1 (TRalpha1). EMBO J. 21, 6452–6460.
13.
KuhlmannT., MironV., CuiQ., WegnerC., AntelJ., and BrückW. (2008). Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain, 131, 1749–1758.
14.
FernándezM., BaldassarroV.A., SiviliaS., GiardinoL., and CalzàL. (2016). Inflammation severely alters thyroid hormone signaling in the central nervous system during experimental allergic encephalomyelitis in rat: direct impact on OPCs differentiation failure. Glia, 64, 1573–1589.
15.
CalzàL., FernándezM., GiulianiA., AloeL., and GiardinoL. (2002). Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 99, 3258–3263.
16.
CalzàL., FernándezM., and GiardinoL. (2015). Role of the thyroid system in myelination and neural connectivity. Compr. Physiol. 5, 1405–1421.
17.
CalzàL., BaldassarroV.A., FernándezM., GiulianiA., LorenziniL., and GiardinoL. (2018). Thyroid hormone and the white matter of the central nervous system: from development to repair. Vitam. Horm. 106, 253–281.
18.
MannilaA., RautioJ., LehtonenM., JärvinenT., and SavolainenJ. (2005). Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases. Eur. J. Pharm. Sci. 24, 101–105.
19.
BassoD.B., BeattieM.S., and BresnahanJ.C. (1995). A sensitive and reliable locomotor rating scale for open field testing in rats. J. Neurotrauma, 12, 1–21.
20.
BaldassarroV.A., KrężelW., FernándezM., SchuhbaurB., GiardinoL., and CalzàL. (2019). The role of nuclear receptors in the differentiation of oligodendrocyte precursor cells derived from fetal and adult neural stem cells. Stem Cell Res. 37, 101443.
21.
OzgenH., BaronW., Hoekstra. D., and KahyaN. (2016). Oligodendroglial membrane dynamics in relation to myelin biogenesis. Cell. Mol. Life Sci. 73, 3291–3310.
22.
DugasJ.C., IbrahimA., and BarresB.A. (2012). The T3-induced gene KLF9 regulates oligodendrocyte differentiation and myelin regeneration. Mol. Cell. Neurosci. 50, 45–57.
23.
PikovV., and WrathallJ.R. (2001). Coordination of the bladder detrusor and the external urethral sphincter in a rat model of spinal cord injury: effect of injury severity. J. Neurosci. 21, 559–569.
24.
WatzlawickR., SenaE.S., DirnaglU., BrommerB., KoppM.A., MacleodM.R., HowellsD.W., and SchwabJ.M. (2014). Effect and reporting bias of RhoA/ROCK-blockade intervention on locomotor recovery after spinal cord injury: a systematic review and meta-analysis. JAMA Neurol. 71, 91–99.
25.
Redondo-CastroE., and NavarroX. (2014). Chronic ibuprofen administration reduces neuropathic pain but does not exert neuroprotection after spinal cord injury in adult rats. Exp. Neurol. 252, 95–103.
26.
SharpK.G., YeeK.M., StilesT.L., AguilarR.M., and StewardO. (2013). A re-assessment of the effects of treatment with a non-steroidal anti-inflammatory (ibuprofen) on promoting axon regeneration via RhoA inhibition after spinal cord injury. Exp. Neurol. 248, 321–337.
27.
StreijgerF., LeeJ.H., DuncanG.J., NgM.T., AssinckP., BhatnagarT., PlunetW.T., TetzlaffW., and KwonB.K. (2014). Combinatorial treatment of acute spinal cord injury with ghrelin, ibuprofen, C16, and ketogenic diet does not result in improved histologic or functional outcome. J. Neurosci. Res. 92, 870–883.
28.
ParepallyJ.M., MandulaH., and SmithQ.R. (2006). Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm. Res. 23, 873–881.
29.
AurielE., RegevK., and KorczynA.D. (2014). Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. Handb. Clin. Neurol. 119, 577–584.
30.
PiresL.R., LopesC.D.F., SalvadorD., RochaD.N., and PêgoA.P. (2017). Ibuprofen-loaded fibrous patches-taming inhibition at the spinal cord injury site. J. Mater. Sci. Mater. Med. 28, 157.
31.
ChewL.J., and DeBoyC.A. (2016). Pharmacological approaches to intervention in hypomyelinating and demyelinating white matter pathology. Neuropharmacology, 110, 605–625.
32.
LeeJ.Y., and PetratosS. (2016). Thyroid hormone signaling in oligodendrocytes: from extracellular transport to intracellular signal. Mol. Neurobiol. 53, 6568–6583.
33.
HassannejadZ., Shakouri-MotlaghA., MokhatabM., ZadeganS.A., Sharif-AlhoseiniM., ShokranehF., and Rahimi-MovagharV. (2019). Oligodendrogliogenesis and axon remyelination after traumatic spinal cord injuries in animal studies: a systematic review. Neuroscience, 402, 37–50.
34.
BilliardsS.S., HaynesR.L., FolkerthR.D., BorensteinN.S., TrachtenbergF.L., RowitchD.H., LigonK.L., VolpeJ.J., and KinneyH.C. (2008). Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia. Brain Pathol. 18, 153–163.
35.
Valentin-TorresA., SavarinC., BarnettJ., and BergmannC.C. (2018). Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation. J. Neuroinflammation, 15, 121.
36.
BannwarthB., LapicqueF., PehourcqF., GilletP., SchaeverbekeT., LabordeC., DehaisJ., GaucherA., and NetterP. (1995). Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. Br. J. Clin. Pharmacol. 40, 266–269.
37.
IshiiD., YingT.H., MaharaA., MurakamiS., YamaokaT., LeeW.K., and IwataT. (2009). In vivo tissue response and degradation behavior of PLLA and stereocomplexed PLA nanofibers. Biomacromolecules, 10, 237–242.
38.
PhillisJ.W., and O'ReganMH. (1996). Mechanisms of glutamate and aspartate release in the ischemic rat cerebral cortex. Brain Res. 730, 150–164.
39.
LiS., MealingG.A., MorleyP., and StysP.K. (1999). Novel injury mechanism in anoxia and trauma of spinal cord white matter: glutamate release via reverse Na+-dependent glutamate transport. J. Neurosci. 19,RC16.
40.
SheldonA.L., and RobinsonM.B. (2007). The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem. Int. 51, 333–355.
41.
ParkE., VelumianA.A., and FehlingsM.G. (2004). The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. J. Neurotrauma, 21, 754–774.
42.
BadhiwalaJ.H., AhujaC.S., and FehlingsM.G. (2018). Time is spine: a review of translational advances in spinal cord injury. J. Neurosurg. Spine, 30, 1–18.
43.
Gomes-OsmanJ., CortesM., GuestJ., and Pascual-LeoneA. (2019). Systematic review of experimental strategies aimed at improving motor function after acute and chronic spinal cord injury. J. Neurotrauma, 33, 425–438.
44.
LiuD., ShanY., ValluruL., and BaoF. (2013). Mn (III) tetrakis (4-benzoic acid) porphyrin scavenges reactive species, reduces oxidative stress, and improves functional recovery after experimental spinal cord injury in rats: comparison with methylprednisolone. BMC Neurosci. 14, 23.
45.
MarconR.M., CristanteA.F., de Barros FilhoT.E., de OliveiraR.P., and dos SantosG.B. (2010). Potentializing the effects of GM1 by hyperbaric oxygen therapy in acute experimental spinal cord lesion in rats. Spinal Cord, 48, 808–813.
46.
JiaY.F., GaoH.L., MaL.J., and LiJ. (2015). Effect of nimodipine on rat spinal cord injury. Genet. Mol. Res. 14, 1269–1276.
47.
AhmadM., ZakariaA., and AlmutairiK.M. (2016). Effectiveness of minocycline and FK506 alone and in combination on enhanced behavioral and biochemical recovery from spinal cord injury in rats. Pharmacol. Biochem. Behav. 145, 45–54.
48.
MuX., AzbillR.D., and SpringerJ.E. (2000). Riluzole and methylprednisolone combined treatment improves functional recovery in traumatic spinal cord injury. J. Neurotrauma, 17, 773–780.
49.
DerghamP., EllezamB., EssagianC., AvedissianH., LubellW.D., and McKerracherL. (2002). Rho signalling pathway targeted to promote spinal cord repair. J. Neurosci. 22, 6570–6577.
50.
ChenW.F., ChenC.H., ChenN.F., SungC.S., and WenZ.H. (2015). Neuroprotective effects of direct intrathecal administration of granulocyte colony-stimulating factor in rats with spinal cord injury. CNS Neurosci. Ther. 21, 698–707.
51.
LiebscherT., SchnellL., SchnellD., SchollJ., SchneiderR., GulloM., FouadK,. MirA., RauschM., KindlerD., HamersF.P., and SchwabM.E. (2005). Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. Ann. Neurol. 58, 706–719.
52.
OkadaS., HaraM., KobayakawaK., MatsumotoY., and NakashimaY. (2018). Astrocyte reactivity and astrogliosis after spinal cord injury. Neurosci. Res. 126, 39–43.
53.
DuncanG.J., ManeshS.B., HiltonB.J., AssinckP., LiuJ., MoulsonA., PlemelJ.R., and TetzlaffW. (2018). Locomotor recovery following contusive spinal cord injury does not require oligodendrocyte remyelination. Nat. Commun. 9, 3066.
54.
HassannejadZ., Shakouri-MotlaghA., MokhatabM., ZadeganS.A., Sharif-AlhoseiniM., ShokranehF., and Rahimi-MovagharV. (2019). Oligodendrogliogenesis and axon remyelination after traumatic spinal cord injuries in animal studies: a systematic review. Neuroscience, 402, 37–50.
55.
QiL., JiangH., CuiX., LiangG., GaoM., HuangZ., and XiQ. (2017). Synthesis of methylprednisolone loaded ibuprofen modified dextran based nanoparticles and their application for drug delivery in acute spinal cord injury. Oncotarget, 8, 99666–99680.
56.
ShultzR.B., WangZ., NongJ., ZhangZ., and ZhongY. (2017). Local delivery of thyroid hormone enhances oligodendrogenesis and myelination after spinal cord injury. J. Neural Eng. 14, 036014.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
